Table 1.

A comparative representation of studies describing molecular reclassification of meningiomas.

	Bayley et al, 2022 (10)			Nassiri et al, 2021 (7)				Maas et al, 2021 (8)
	MenG A	MenG B	MenG C	Group 1	Group 2	Group 3	Group 4	Subtype 1 (Low)	Subtype 2 (Int)	Subtype 3 (High)
TRAF7
AKT1
KLF4
SMO		N/A						N/A	N/A	N/A
POLR2A								N/A	N/A	N/A
SMARCB1								N/A	N/A	N/A
Chr22q Loss
NF2
Chr1p Loss
TERT	N/A	N/A	N/A

Within each classification scheme, meningioma subgroups are ordered from left to right based on increasingly worse progression free survival. Genetic mutations and chromosomal losses were compared across each subgroup with black shading indicating predominant mutation/loss in that group, empty cell indicating that the mutation/loss was tested for but was not present or significantly less predominant in that group, and N/A indicating that the mutation/loss was not tested for or not reported in that study.